Abstract:Background: Ischemic stroke is an acute cerebrovascular disease with high mortality rates and poor prognoses. The influence of ischemic stroke includes a heavy economic burden to patients and society, making the exploration of new therapeutic targets for preventing and treating ischemic stroke urgent. This study aimed to explore the effect of phosphoglycerate mutase family member 5 (PGAM5) on oxidative stress and mitochondrial dysfunction in ischemic stroke. Methods: The model of ischemic neuronal brain injury was established through culturing purchased human neuroblastoma cells (SH-SY5Y) by oxygen-glucose deprivation/reoxygenation (OGD/R). There were six experimental groups, including the OGD/R model group (SH-cells of OGD/R model), OE-NC group (cells of OGD/R model transfected with scramble cDNA), OE-PGAM5 group (cells of OGD/R model transfected with full-length sequence of PGAM5), si-NC group (cells of OGD/R model transfected with negative control small interference (si)RNA), si-PGAM5 group (cells of OGD/R model transfected with siRNA for PGAM5 knockdown), and a control group (cells cultured normally). Cell counting kit-8 (CCK-8) and flow cytometry were used to determine the activity and apoptosis of cells. Subsequently, the effects of PGAM5 expression on oxidative stress and mitochondrial dysfunction were analyzed. Mitochondrial morphology was observed by transmission electron microscopy (TEM), and mitochondrial membrane potential (MMP) was determined by JC-1 fluorescent probe. The levels of reactive oxygen species (ROS) were measured by flow cytometry, and levels of malondialdehyde (MDA) and superoxide dismutase (SOD) were measured by enzyme-linked immunosorbent assay (ELISA) assay. The expression of light chain (LC)3-II/I and autophagy-related gene 5 (ATG5) proteins were measured, and the regulation of PGAM5 expression on PTEN-induced putative protein kinase 1 (PINK1)/Parkin pathway was also explored. Results: PGAM5 overexpression in OGD/R cells decreased the cell viability (p < 0.001) while increasing cell apoptosis (p < 0.01) compared to the OGD/R group. Inhibition of PGAM5 expression reversed the decreased cell viability (p < 0.001) and the increased cell apoptosis (p < 0.01). The JC-1 fluorescence showed that OGD/R treatment reduced mitochondrial membrane potential (p < 0.001) and TEM showed an obvious increase in phagosomes. In addition, OGD/R treatment enhanced oxidative stress (increased ROS, p < 0.01; increased MDA, p < 0.001; decreased SOD, p < 0.001), which could be further enhanced by overexpression of PGAM5 (ROS, p < 0.001; MDA, p < 0.001; SOD, p < 0.001) while reversed by the inhibition of PGAM5 (ROS, p < 0.01; MDA, p < 0.001; SOD, p < 0.001). The OGD/R-activated PINK1/Parkin pathway was inhibited by the knockdown of PGAM5 (p < 0.01) but promoted by the overexpression of PGAM5 (p < 0.05). Conclusions: PGAM5 stimulates oxidative stress and impairs mitochondrial function in ischemic stroke, and regulates the PINK1/Parkin signaling pathway. Therefore, PGAM5 is likely to be a target for the therapy of ischemic stroke.

Differential effects of PGAM5 knockout on high fat high fructose diet and methionine choline-deficient diet induced non-alcoholic steatohepatitis (NASH) in mice

Ganoderic Acid A Ameliorates Non-Alcoholic Streatohepatitis (NASH) Induced by High-Fat High-Cholesterol Diet in Mice

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

PGC1 protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response

PGC1α protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response.

Deletion of PGAM5 Downregulates FABP1 and Attenuates Long-Chain Fatty Acid Uptake in Hepatocellular Carcinoma

Proteomic Analysis of Liver Mitochondria from Rats with Nonalcoholic Steatohepatitis

Effect of Mir-146 Targeted Hdmcp Up Regulation in the Pathogenesis of Nonalcoholic Steatohepatitis

Osteoprotegerin Deficiency Aggravates Methionine–choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis in Mice

Phosphoglycerate mutase 5 aggravates alcoholic liver disease through disrupting VDAC-1-dependent mitochondrial integrity

Hepatic‐specific Pgc‐1α ablation drives fibrosis in a MASH model

Phosphoglycerate Mutase 5 Exacerbates Liver Ischemia–reperfusion Injury by Activating Mitochondrial Fission

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model

Fatty liver is associated with impaired activity of PPARγ-coactivator 1α (PGC1α) and mitochondrial biogenesis in mice

Regulation of the Macrophage-Hepatic Stellate Cell Interaction by Targeting Macrophage Peroxisome Proliferator-Activated Receptor Gamma to Prevent Non-Alcoholic Steatohepatitis Progression in Mice

Coordinated Changes of Gut Microbiome and Lipidome Differentiates Nonalcoholic Steatohepatitis (NASH) from Isolated Steatosis.

514 - Cell Type-Specific Function of P38α MAPK in Non-Alcoholic Steatohepatitis: the Crosstalk Between Hepatocytes and Macrophages

The Pharmacodynamic And Differential Gene Expression Analysis Of Ppar Alpha/Delta Agonist Gft505 In Cdahfd-Induced Nash Model

MFG-E8 Knockout Aggravated Nonalcoholic Steatohepatitis by Promoting the Activation of TLR4/NF-κB Signaling in Mice

The Effect of PGAM5 on Regulating Mitochondrial Dysfunction in Ischemic Stroke

Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1α